Document is current
Any future updates will be listed below
-
Authors
Facheris, Paola https://orcid.org/0000-0002-5171-9854
Piscazzi, Francesco https://orcid.org/0000-0001-9495-6350
Fiorillo, Giovanni https://orcid.org/0000-0002-3089-4362
Valenti, Mario https://orcid.org/0000-0001-9140-9263
Costanzo, Antonio https://orcid.org/0000-0001-9697-2557
Borroni, Riccardo G. https://orcid.org/0000-0002-5704-1220
-
Funding
Funding for this research was provided by:
Almirall
- License Information
-
More Information
Article History
Received: 4 February 2026
Accepted: 7 April 2026
First Online: 24 April 2026
Declarations
:
: Paola Facheris has served as a consultant for Eli Lilly and as a speaker for UCB, Abbvie, La Roche-Posay, and Pfizer. Francesco Piscazzi has no conflict of interest to declare. Giovanni Fiorillo has served as consultant and/or speaker for Novartis, LeoPharma, Bristol Meyer Squibb, Incyte, and Eli Lilly. Mario Valenti has served as consultant and/or speaker for Novartis, Almirall, Eli-Lilly, Abbvie, Johnson&Johnson, UCB, Boehringer-Ingelheim, Difa Cooper, Sun-Pharma, Leo Pharma, and Bristol Myers Squibb. Antonio Costanzo has served as an advisory board member and consultant and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Almirall, Biogen, LEO Pharma, Eli-Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB. Riccardo G. Borroni has served as consultant in scientific board for Almirall and Istituto Gentili.
: The study was approved by the institutional review board (protocol no. 3083) and conducted in accordance to the Helsinki Declaration of 1964. All subjects provided informed consent to participate in the study.
